课题基金 / 基金详情

项目摘要

项目成果

ROY M. GULICK的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): An estimated 1 million Americans (and more than 90,000 New York City residents) have HIV infection. Despite recent advances, HIV/AIDS remains an important area for clinical investigation. This application describes the Cornell Clinical Trials Unit (CCTU), an HIV/AIDS therapeutic clinical trials unit that will affiliate with the 3 AIDS Clinical Trials Group (ACTG) network by prior agreement. The Cornell unit consists of an overall administrative core and two CRSs: Cornell Uptown and Cornell Chelsea. The core unit provides central research support to the CRSs including: investigative oversight, administration, study coordination, data management, regulatory, outreach, and pharmacy services. The two clinical research sites CRSs are located in different parts of New York City, in or close to the neighborhoods with the highest HIV seroprevalence rates: Cornell Uptown is located close to East Harlem (2.5% seroprevalence) and Cornell Chelsea is located in Chelsea-Clinton (4.1% seroprevalence). The two CRSs serve distinct patient populations that include significant numbers of women, people of color (African Americans, Asians, and Latinos), and adolescents/young adults from diverse risk groups (heterosexuals, injection drug users, men who have sex with men). With 17 years experience in the ACTG, the Cornell unit has broad scientific and clinical research experience in diverse areas including: antiretroviral agents and strategies; complications of HIV and antiretroviral therapies; immune-based therapies, including vaccines; co-infections (e.g. hepatitis B, hepatitis C, and human papillomavirus); neurological complications; adherence and outcomes; HIV-infected women and pregnancy; and prevention of mother-to-child transmission of HIV. The Cornell unit will contribute to the priority research areas of the ACTG: translational research/drug development; optimization of clinical management, including co-morbidities; therapeutic vaccine research and development; and prevention of mother-to-child transmission. Cornell investigators serve in ACTG leadership positions, on ACTG committees, and ACTG protocol teams (including protocol leadership for 11 current studies). Cornell has strong ties to Haiti and plays an active role in mentoring and training Haitian HIV/AIDS clinical investigators. A major focus of the Cornell unit is community outreach and education and the Cornell Community Advisory Board is active in representing our diverse community. ADMINISTRATIVE COMPONENT:
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1007/s11904-011-0077-5
发表时间: 2011-06-01
期刊: Current HIV/AIDS reports
影响因子: 4.6
作者: [Vogler, Mary A, Singh, Harjot, Wright, Rodney]
通讯作者: Wright, Rodney
Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial.
HIV 治疗简化的潜在风险和益处:拟议临床试验的模拟模型。
DOI: 10.1086/521933
发表时间: 2007
期刊: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
影响因子: --
作者: [Schackman,BruceR, Scott,CallieA, Sax,PaulE, Losina,Elena, Wilkin,TimothyJ, McKinnon,JohnE, Swindells,Susan, Weinstein,MiltonC, Freedberg,KennethA]
通讯作者: Freedberg,KennethA
DOI: 10.1097/qai.0b013e3182690e3c
发表时间: 2012-11-01
期刊: Journal of acquired immune deficiency syndromes (1999)
影响因子: --
作者: [Krishnan S, Schouten JT, Atkinson B, Brown T, Wohl D, McComsey GA, Glesby MJ, Shikuma C, Haubrich R, Tebas P, Campbell TB, Jacobson DL]
通讯作者: Jacobson DL
Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development.
添加一种可改善 HIV 感染患者初始抗逆转录病毒治疗 (ART) 免疫反应的药物的成本效益:药物开发指南。
DOI: 10.1310/hct1301-001
发表时间: 2012
期刊: HIV clinical trials
影响因子: --
作者: [Morris,BethanyL, Scott,CallieA, Wilkin,TimothyJ, Sax,PaulE, Gulick,RoyM, Freedberg,KennethA, Schackman,BruceR]
通讯作者: Schackman,BruceR
WCM-Rutgers NJMS CTU Supplement for COVID Testing
Cornell Clinical Trials Unit
Cornell Clinical Trials Unit
Weill Cornell Medical College-New Jersey Medical School Clinical Trials Unit